Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cubist buys Optimer for $524mm in cash, plus CVRs

Executive Summary

Acute care firm Cubist Pharmaceuticals Inc. is acquiring all the outstanding common stock of public antibiotics developer Optimer Pharmaceutical Inc. for $10.75 per share (a 24% discount) in cash, or a total of $523.7mm. The transaction also includes earn-outs in the form of contingent value rights (CVRs), which would give Optimer shareholders up to $5.00 for each share they own--a total of $243.6mm--if certain net sales of Dificid (fidaxomicin) are met.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies